- As lucrative investments, gene therapy companies also are delivering hope for countless patients worldwide. Early-bird investors already secured sizable profits, but the best is yet to come.
- My research revealed that Regenxbio is a leading gene therapy innovator that will ultimately deliver many stellar therapeutics to patients and handsomely reward investors.
- Novartis is most likely to gain FDA approval of Zolgensma to manage a lethal genetic condition coined spinal motor atrophy Type 1.
- The most promising organic asset, RGX-314 is well positioned to capture the mega-blockbuster age-related macular degeneration market.
- I valued all pipeline molecules and provided the new "investment profitability forecasting" to empower you with nearly prescient knowledge.
- Looking for more? I update all of my investing ideas and strategies to members of Integrated BioSci Investing. Start your free trial today »
History has shown that in every age and in every field of human knowledge, many of the views which almost everyone accepted as true and never bothered to think about further, were in time proven completely wrong. - Phillip Fisher (Warren Buffett's Teacher)
The largest profits are usually derived from investing in an emerging industry operating at a "growth inflection." That being said, gene therapy is hitting its growth spurts after over a decade of early setbacks. It's now a lucrative field delivering substantial profits for investors and hopes for countless patients worldwide. While gene therapy is a fertile investment field, it's important that you select the most outstanding innovators instead of "run of the mill" stocks: Building stakes in leading companies usually deliver the most gargantuan returns. In researching many gene therapy issues, Regenxbio (RGNX) stood out as the most promising prospect. Asides from brewing an organic pipeline, this "cream of the crop" operator is advancing what I believe is the best gene therapy platform. In this unprecedented research, I'll conduct a deep-dive fundamental analysis on Regenxbio. My hope is that after reading this IBI article, you'll be empowered with expert knowledge to be confident in whether you should purchase this company.
